- Home
- CHRW vs ROIV Comparison
CHRW vs ROIV Comparison
Compare CHRW & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHRW | ROIV |
|---|---|---|
| Founded | 1905 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0B | 19.6B |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CHRW | ROIV |
|---|---|---|
| Price | $184.80 | $28.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 8 |
| Target Price | ★ $174.53 | $27.44 |
| AVG Volume (30 Days) | 3.2M | ★ 6.1M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.37% | N/A |
| EPS Growth | ★ 25.13 | N/A |
| EPS | ★ 4.83 | N/A |
| Revenue | ★ $14,869,380,000.00 | $29,053,000.00 |
| Revenue This Year | $4.33 | N/A |
| Revenue Next Year | $6.54 | $400.59 |
| P/E Ratio | $38.09 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $84.68 | $8.73 |
| 52 Week High | $203.34 | $29.20 |
Technical Indicators
Market Signals| Indicator | CHRW | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 52.13 | 72.76 |
| Support Level | $148.27 | $20.46 |
| Resistance Level | $203.34 | N/A |
| Average True Range (ATR) | 10.05 | 0.95 |
| MACD | -1.40 | 0.16 |
| Stochastic Oscillator | 66.10 | 89.37 |
Price Performance
Historical ComparisonAbout CHRW C.H. Robinson Worldwide Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 60% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (30%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of transportation management services and a legacy produce-sourcing operation.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.